Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the earl...

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1/programmed ligand-1 axis have significantly shifted the treatment paradigm in advanced NSCLC, clinical benefits of these agents are limited patients with EGFR-mutated NSCLC. Several predictive biomarkers (e.g., expression, tumor mutation burden), which been validated EGFR-wild type however, not efficacious ...

BACKGROUND Antibody therapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) is a promising therapy in human cancer, but only limited information on PD-L1 expression in canine tumors is available. MATERIALS AND METHODS PD-L1 expression was examined in 31 canine tumor cell lines of various origins by flow cytometry and western blotting, and in canine tumor an...

The purpose of this study was to investigate the efficacy and safety of programmed cell death 1 (PD-1) and programmed cell death 1 ligand (PD-L1) inhibitors using a meta-analysis of present trials for advanced melanoma. A fully recursive literature search of the primary electronic databases for available trials was performed. The objective response rate (ORR) and the median progression-free sur...

Summary We characterised patients with mantle cell lymphoma (MCL) poor prognosis based on differences in immune infiltration. Different expressions of the tumour markers Cyclin D1 and sex‐determining region Y‐box transcription factor 11 (SOX11), cluster differentiation 3 (CD3), CD4, CD8, CD25, forkhead box protein P3 (FoxP3), T‐box TBX21 (T‐bet), programmed death 1 (PD‐1), programmed‐death liga...